New pill aims to beat chemo fatigue: AND017 trial launches
NCT ID NCT06075030
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an oral drug called AND017 for cancer-related anemia caused by chemotherapy. About 36 adults with non-myeloid cancers and low hemoglobin will take AND017 three times a week for 6 weeks. The goal is to see if it safely raises hemoglobin levels and reduces the need for blood transfusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AND017 (oral capsules)
What this could lead to
If it works, this could offer a new way to treat anemia caused by chemotherapy, helping patients feel less tired and avoid blood transfusions.
What could go wrong
This is an early Phase 2 trial with only 36 people, so results may not apply broadly. The drug might not raise hemoglobin enough or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER-RELATED ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••